EUDA Launches Nationwide Stem Cell Extraction, Cryostorage and Clinical Delivery Platform in China with Shenzhen Inno Immune and Wuhan Kaien Hospital

Rhea-AI Summary

EUDA (NASDAQ: EUDA) announced on December 30, 2025 the launch of a nationwide stem cell extraction, cryostorage and clinical delivery platform in China in partnership with Shenzhen Inno Immune and Wuhan Kaien Hospital. The platform combines centralized processing with decentralized clinical access, cold-chain logistics and integration into longevity medicine.

Key infrastructure includes an initial ~50,000 patient-unit cryogenic hub in Shenzhen and a planned ~200,000 patient-unit capacity at Wuhan Kaien, plus a partner network of extraction clinics and regulated transport for sample movement and clinical delivery.

Positive

• Shenzhen hub initial capacity ~50,000 patient cell units
• Wuhan Kaien planned capacity ~200,000 patient cell units
• Nationwide partner network with ~200 preparation and treatment clinics
• Integrated cold-chain logistics for regulated intercity sample transport
• Centralized processing with decentralized clinic access for scalability

Negative

• None.

Key Figures

Shenzhen storage capacity approximately 50,000 patient cell units Initial designed cryogenic storage capacity at Shenzhen Inno Immune hub

Wuhan biostorage capacity approximately 200,000 patient cell units Planned cryogenic biostorage and clinical capacity at Wuhan Kaien Hospital

Clinic network size approximately 200 clinics Guangdong Wanhai’s preparation and treatment clinics across China

Geographic reach more than 20 provinces and cities Coverage of Guangdong Wanhai’s national footprint in China

Convertible note capacity US$10,000,000 Maximum Convertible Promissory Notes capacity under prior prospectus

Convertible notes sold US$1,000,000 Aggregate principal amount of Convertible Notes sold

CK Health acquisition value US$15.0 million Share-based acquisition consideration for CK Health

Impairment on intangibles US$14,762,562 Impairment related to CK Health intangible assets

Market Reality Check

$2.34 Last Close

Volume Volume 150,319 is below the recent average of 655,734, indicating muted trading interest ahead of this expansion news. low

Technical Shares at $2.34 are trading below the $2.99 200-day moving average, reflecting a weaker longer-term trend.

Peers on Argus

EUDA fell 4.49% while key peers showed mixed, mostly modest moves (e.g., RFL -0.83%, OMH -3.7%, DUO -1.26%, NYC +0.31%), suggesting a stock-specific reaction rather than a broad sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 23	Stem cell platform launch	Positive	+41.2%	Launch of stem cell platform and first longevity clinic in Shenzhen.
Dec 22	Crypto rewards integration	Positive	-51.4%	Integration of QB utility token into digital health and rewards platform.
Dec 08	Planned token integration	Positive	+8.5%	Plans to integrate QB cryptocurrency into healthcare ecosystem from Jan 2026.
Dec 05	Convertible warrant financing	Positive	-6.8%	Securities purchase agreement for a convertible warrant to fund expansion.
Oct 23	India expansion partnership	Positive	-15.5%	CK Health Plus expansion into India via partnership with SafeRock India.

Pattern Detected

Recent EUDA news often shows mixed or contrarian price reactions, with several strategic or financing updates followed by negative 24-hour moves.

Recent Company History

Over the last few months, EUDA has announced multiple strategic initiatives across regenerative medicine and digital health. On Dec 23, 2025, it launched a comprehensive stem cell therapy platform and opened its first longevity clinic in Shenzhen, which coincided with a 41.18% move higher. On Dec 22, integrating the QB utility token into its ecosystem saw shares drop 51.43%. A US$100,000 securities purchase agreement for a convertible warrant on Dec 5 led to a -6.85% reaction. Earlier, an India expansion partnership on Oct 23 saw shares fall 15.49%.

Market Pulse Summary

This announcement extends EUDA’s regenerative medicine footprint by linking nationwide stem cell extraction, centralized processing, cryogenic storage and clinical delivery across China, anchored by Shenzhen Inno Immune and Wuhan Kaien Hospital with capacity targets up to about 200,000 cell units. In recent months, EUDA has layered on token-based rewards, international expansion and convertible-note financing alongside a US$14,762,562 impairment. Investors may track utilization of the clinic network, actual storage volumes, and the impact of prior financings on future strategic flexibility.

Key Terms

cold-chain technical

"transported under cold-chain protocols to Shenzhen Inno Immune or Wuhan Kaien Hospital"

A cold-chain is the refrigerated logistics system that keeps temperature-sensitive products—such as vaccines, biologic drugs, and perishable foods—within a controlled temperature range from production through storage and transport to the end user. Investors care because failures in this “continuous refrigerator” can destroy product value, trigger costly recalls or regulatory penalties, and require specialized infrastructure and ongoing operating costs that affect margins and growth potential.

chain-of-custody technical

"with logistics coordination and chain-of-custody tracking managed through dedicated"

A chain-of-custody is the documented trail showing who handled, transferred, stored and accessed an asset, sample or record from origin to its final destination. Think of it like a series of signed receipts that prove an item was tracked and not tampered with. Investors care because a clear chain-of-custody preserves evidence, regulatory compliance and product integrity, reducing legal, valuation and operational risks that can affect company value.

AI-generated analysis. Not financial advice.

SINGAPORE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company,” a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced the launch of its nationwide stem cell extraction, cryogenic storage and clinical delivery platform in China. The Company has partnered with Shenzhen Inno Immune Co., Ltd. and Wuhan Kaien Hospital as the Company continues to expand its national clinical and logistics network. This platform marks a major step in EUDA’s continued advancement of its stem cell strategy, further extending its capabilities across cell extraction, processing, cryogenic storage, logistics and clinical application.

Core Platform Design Principles

EUDA’s platform is designed around three core principles: centralized processing with decentralized access to ensure quality and compliance without limiting geographic reach, long-term cell preservation to enable patients to store biological material earlier in life for potential future clinical use, and integration with longevity medicine so that cell services are embedded within broader preventive, regenerative and personalized health programs.

National Stem Cell Extraction and Cryostorage Infrastructure

EUDA’s platform is designed as a closed-loop, compliant operating system that enables patients to access stem cell services across a wide geographic footprint while maintaining centralized processing standards.

Key elements include:

• Shenzhen Inno Immune Co., Ltd. as EUDA’s primary cell processing and cryogenic storage hub in Southern China, with an initial designed cryogenic storage capacity of approximately 50,000 patient cell units under controlled conditions.

• Wuhan Kaien Hospital as EUDA’s Central China clinical and longevity flagship, with a planned cryogenic biostorage and clinical capacity designed to support up to approximately 200,000 patient cell units, integrated with inpatient, outpatient and long-term health management services.

• A nationwide clinical access layer via partner clinic networks enabling local extraction and downstream clinical delivery.

Wuhan Kaien Hospital

Wuhan Kaien Hospital is a premium longevity-focused health management hospital positioned as a five-star, integrated anti-aging and preventive healthcare center that brings together regenerative medicine, non-drug chronic disease management, hormone and metabolic balance, immune support, early-warning diagnostics and personalized long-term health planning within one institutional setting. It was established as a flagship model for integrating advanced diagnostics and early disease risk detection, regenerative and cell-based medical technologies, personalized health management programs and multidisciplinary clinical teams spanning regenerative medicine, endocrinology, cardiovascular health, immune health and longevity science. Under EUDA’s platform, Wuhan Kaien Hospital will serve both as a clinical delivery site and as a central node for stem cell processing, storage and clinical translation in Central China.

Distributed Clinical Access and Centralized Processing Network

To enable nationwide access, EUDA is working with two strategic infrastructure partners. Guangdong Wanhai Cell Biotechnology Co., Ltd. operates a nationwide footprint comprising cGMP-standardized laboratories, regional cell preparation centers and affiliated clinical preparation and treatment sites, and an extensive network of approximately 200 preparation and treatment clinics across more than 20 provinces and cities in China, providing physical access points where eligible patients can undergo extraction, clinical preparation and post-processing coordination. Shunfeng Cold Chain Logistics Co., Ltd. specializes in regulated, temperature-controlled intercity transport of cellular and biological materials and supports the secure movement of patient samples between extraction clinics, processing facilities and treatment centers under controlled cold-chain conditions.

Through this integrated structure, patients may undergo stem cell extraction at participating clinics within the national partner network, after which extracted cellular material is transported under cold-chain protocols to Shenzhen Inno Immune or Wuhan Kaien Hospital for processing and cryogenic storage. When clinically appropriate, prepared cell products are transported back to designated clinics for patient administration, with logistics coordination and chain-of-custody tracking managed through dedicated biomedical cold-chain systems. This architecture allows EUDA to offer geographically distributed access with centralized quality control, supporting scalability while maintaining processing consistency.

Mr Alfred Lim, CEO of EUDA, commented:

“This platform transforms how regenerative medicine is accessed and delivered in China. Instead of isolated clinics or laboratories, we are building a coordinated national system connecting extraction, cryogenic storage, logistics and clinical delivery into one integrated ecosystem. With Shenzhen Inno Immune and Wuhan Kaien Hospital as our anchors, and our national clinic and logistics partners extending reach, we believe we are creating a comprehensive and scalable infrastructure for regenerative medicine access in the region.”

About EUDA Health Holdings Limited

EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.

Forward-Looking Statements

This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact

Christensen Advisory
Linda Bergkamp
Phone: +1-480-614-3004
E-mail: linda.bergkamp@christensencomms.com

FAQ

What did EUDA announce on December 30, 2025 about its China operations?

EUDA launched a nationwide stem cell extraction, cryostorage and clinical delivery platform in China with Shenzhen Inno Immune and Wuhan Kaien Hospital.

What cryogenic storage capacities did EUDA disclose for Shenzhen and Wuhan (EUDA)?

Shenzhen Inno Immune has an initial designed capacity of ~50,000 patient cell units; Wuhan Kaien is planned for ~200,000 patient cell units.

How will patients access EUDA’s stem cell services across China (EUDA)?

Patients access extraction locally at partner clinics, then samples are transported under cold-chain protocols to centralized processing and storage hubs.

Which logistics partner supports EUDA’s sample transport in China (EUDA)?

Shunfeng Cold Chain Logistics will manage regulated, temperature-controlled intercity transport and chain-of-custody tracking.

How many clinics are in the partner network supporting EUDA’s platform (EUDA)?

The network includes approximately 200 preparation and treatment clinics across more than 20 provinces and cities.

What role will Wuhan Kaien Hospital play in EUDA’s China platform (EUDA)?

Wuhan Kaien will act as a central clinical delivery site and a flagship node for processing, storage and clinical translation in Central China.